Menu
Not yet recruiting NCT07470086

The Role of Environmental Temperatures in Respiratory Control

No phase Interventional Work of Breathing

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Thermoneutral temperature environment, Cold temperature environment, Hot temperature environment.
Who it may be relevant to
Registry conditions: Work of Breathing. Basic parameters: 18 years — 40 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Optimizing Mind-Body Interactions in Respiratory Control During Operationally Relevant Environmental Stressors

Overview

Warfighters are frequently exposed to environments and life-support systems that increase breathing resistance and the work of breathing (WOB), such as aircraft on-board oxygen generation systems and underwater breathing apparatuses. Elevated WOB increases the perception of breathing difficulty (dyspnea) and has been associated with impaired cognitive performance, including slower reaction time and reduced accuracy during attention-demanding tasks. These effects are particularly concerning in operational settings that require rapid decision-making and precise motor responses. Despite growing recognition of this issue, critical gaps remain regarding strategies to mitigate the perceptual and cognitive consequences of elevated inspiratory resistance, especially under realistic operational stressors. The objective of this study is to determine whether exposing individuals to thermal stress alters breathing perception and cognitive performance during inspiratory resistance. Participants will perform inspiratory resistance breathing under thermoneutral, heat, and cold conditions to determine whether thermal stress amplifies WOB, breathing perception, and cognitive impairment.

Detailed description

Warfighters often face thermal stressors that increase the WOB, even with life-support systems in place. Both cold and heat stress elevate the WOB independently, without requiring increased inspiratory resistance. Cold stress stimulates ventilation and causes a biphasic bronchiolar response: inhaling cold air during hyperventilation leads to initial bronchodilation followed by bronchoconstriction, tightening the bronchioles and increasing airflow resistance, and thus the WOB. Warfighters are also exposed to extreme heat and hyperthermia-induced hyperventilation occurs when core body temperature reaches around 38.0°C, significantly correlating with increased WOB during heat stress. Warfighters frequently experience these environmental stressors alongside elevated breathing resistance, especially during underwater diving missions in varying temperatures or in high-performance aircraft with OBOGs exposed to extreme heat.

A critical gap in knowledge exists regarding whether high inspiratory resistance combined with thermal stress amplifies the WOB, altering the perception of breathing and cognitive and physiological responses. The study will investigate the WOB, breathing perception, cognitive function, and physiological responses under combined inspiratory resistance and thermal stress (thermoneutral, heat, and cold). It's hypothesized that WOB will increase during heat and cold stress, resulting in greater perceptions of breathing difficulty and decreased cognitive performance compared to thermoneutral conditions.

Participants will complete 4 study visits: a screening/familiarization visit (Study Day 0) followed by three experimental visits (Study Day 1, Day 2, and Day 3). Participants will be instructed to avoid caffeine, alcohol, stimulant medication, pain/anti-inflammatory medication, cannabis and cannabis related products, and vigorous exercise for at least 24 hours prior to experimental visits. On Study Day 0, participants will complete a short familiarization breathing task in which they will breathe for 10 minutes through an 8-10mm hole at the end of a customized device, generating a pre-determined inspiratory resistance of 6-9.5 centimeters of water per liter per second (cmH2O/L/s). During the breathing task, cerebral vascular, cardiovascular and autonomic activity responses will be measured. Every 5 minutes during the breathing test, participants will be asked to rate breathing intensity and unpleasantness, and perform an inspiratory capacity maneuver. Cognitive assessments will be administered every10 minutes. After the breathing task, participants will complete lung and respiratory muscle function tests.

Prior to the experimental visits, participants will be randomized to the order in which they are exposed to the interventional conditions (hot, cold, or thermoneutral). Upon arrival, an esophageal balloon will be placed to measure the pressure around the heart and lungs. Participants will then be placed into an environmental chamber (to control humidity) while wearing a special suit which allows different temperatures of water to be circulated through tubes which will expose them to the temperature conditions for roughly 30 minutes before starting the full-length breathing tasks. During thermoneutral conditions 34°C water will be perfused through special suit while participants resting the chamber set to 24°C and 40% room humidity. During the cold condition, 4°C water will be perfused through the special suit while participants rest in the chamber set to 4°C and 10% room humidity. The breathing task will commence when esophageal temperature reaches -1°C and -2°C relative to baseline esophageal temperature. During the hot condition, 50°C water will be perfused through the special suit while participants rest in the chamber set to 40°C and 40% room humidity. The breathing task will commence when esophageal temperature reaches +1°C and +2°C relative to baseline esophageal temperature. At each experimental visit, participants will complete a full-length breathing task, in which they inspire against a predetermined resistive load for 60 minutes. Biometric monitoring will be continuously performed, and cognitive assessments and participant ratings during the breathing tasks will be performed at 45- and 90-minutes of the condition exposure. A 7 day washout period will be observed between the experimental visits.

Interventions

  • Other Thermoneutral temperature environment
    During thermoneutral conditions 34°C water will be perfused through special suit while participants resting the chamber set to 24°C and 40% room humidity.
  • Other Cold temperature environment
    During the cold condition, 4°C water will be perfused through the special suit while participants rest in the chamber set to 4°C and 10% room humidity.
  • Other Hot temperature environment
    During the hot condition, 50°C water will be perfused through the special suit while participants rest in the chamber set to 40°C and 40% room humidity.

Primary outcome measures

  • Change in Stroop Color-Word Test Time Performance [Time frame: Before and after each breathing task on Days 1, 2, 3 (each approximately 90 minutes in duration)]
  • Change in Stroop Color-Word Test Error Performance [Time frame: Before and after each breathing task on Days 1, 2, 3 (each approximately 90 minutes in duration)]
  • Change in Perception of Dyspnea Intensity [Time frame: Before and after each breathing task on Days 1, 2, 3 (each approximately 90 minutes in duration)]
  • Change in Perception of Dyspnea Unpleasantness [Time frame: Before and after each breathing task on Days 1, 2, 3 (each approximately 90 minutes in duration)]
Secondary outcome measures (8)
  • Change in Diaphragm Thickness [Time frame: Before and after each breathing task on Days 1, 2, 3 (each approximately 90 minutes in duration)]
  • Change in Heart Rate Variability [Time frame: Before and after each breathing task on Days 1, 2, 3 (each approximately 90 minutes in duration)]
  • Change in Peripheral Oxygen Saturation [Time frame: Before and after each breathing task on Days 1, 2, 3 (each approximately 90 minutes in duration)]
  • Change in Blood Pressure - Brachial Artery [Time frame: Before and after each breathing task on Days 1, 2, 3 (each approximately 90 minutes in duration)]
  • Change in Blood Pressure - Finger Photoplethysmography [Time frame: Before and after each breathing task on Days 1, 2, 3 (each approximately 90 minutes in duration)]
  • Change in Heart Rate [Time frame: Before and after each breathing task on Days 1, 2, 3 (each approximately 90 minutes in duration)]
  • Change in Cerebral Blood Oxygen Kinetics [Time frame: Before and after each breathing task on Days 1, 2, 3 (each approximately 90 minutes in duration)]
  • Change in Cerebral Blood Velocity [Time frame: Before and after each breathing task on Days 1, 2, 3 (each approximately 90 minutes in duration)]

Eligibility criteria

Inclusion criteria

  • Between the ages of 18-40 years old.
  • English speaking and reading.
  • Self-reported weekly activity of at least 120 minutes/week of high intensity exercise for the previous 2 years.
  • Normal pulmonary function assessed by a resting forced expiratory volume in 1 second over forced vital capacity (FEV1/FVC) > 75% of predicted.
  • Normal cognitive function assessed using the Montreal cognitive function test \[18\].
  • Body mass index (BMI) ≤ 35 kg/m2.
  • Females with a regular menstrual cycle that ranges from 21-35 days (eumenorrhea)

Exclusion criteria

  • History of smoking or recreational smoking, cardiovascular disease, renal disease, pulmonary disease (including asthma or exercise-induced asthma), neurological disease, and metabolic disease.
  • Are pregnant or could possibly be pregnant by self-report.
  • Are color blind.
  • Known allergy or hypersensitivity latex.
  • Take selective serotonin reuptake inhibitors, stimulant medication, antibiotics, and chronically consume pain medication (Aleve, Tylenol, etc.).
  • Resting blood pressure of > 130mmHg systolic or 90 mmHg diastolic and/or resting pulse rate of > 100 bpm.
  • Females with irregular menstrual cycles (oligomenorrhea) that ranges from 36-90 days, and females with the absence of a menstrual cycle (amenorrhea).
  • Taking birth control for the sole purpose of period cessation (eg., Mirena IUD)

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: Yes

Study design

Allocation
Randomized
Model
Crossover
Masking
Open label
Primary purpose
Basic science

Study locations

United States · 1 center
  • Multidisciplinary Engineering and Sciences Hall (MESH) — Bloomington

Identifiers

NCT: NCT07470086 · 28381 - Aim 3 · FOAAFRLAFOSR20240007

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗